1.35  -0.01 (-0.74%)		12-15 15:59
Open: 1.38 High: 1.385 Volume: 633,319		Pre. Close: 1.36 Low: 1.25 Market Cap: 50(M)

Short term
Mid term
Targets	6-month :	2.04	1-year :	2.38
Resists	First :	1.75	Second :	2.04
Pivot price	1.22
Supports	First :	1.2	Second :	0.87
MAs	MA(5) :	1.41	MA(20) :	1.15
	MA(100) :	1.42	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	69.1	D(3) :	79
RSI	RSI(14): 55.6
52-week	High :	2.74	Low :	0.87

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ MAIA ] has closed below upper band by 31.5%. Bollinger Bands are 81.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.39 - 1.39	1.39 - 1.4
Low:	1.23 - 1.24	1.24 - 1.25
Close:	1.34 - 1.35	1.35 - 1.36

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Thu, 11 Dec 2025
MAIA Biotechnology Announces Significant Insider Buying - TipRanks

Thu, 11 Dec 2025
MAIA Biotechnology, Inc. Announces Key Developments in Cancer Therapy - TradingView — Track All Markets

Thu, 11 Dec 2025
MAIA Biotechnology (NYSE American: MAIA) begins Phase 3 NSCLC study of telomere-targeting ateganosine - Stock Titan

Thu, 11 Dec 2025
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates - GlobeNewswire

Thu, 11 Dec 2025
MAIA - MAIA Biotechnology Inc. Latest Stock News & Market Updates - Stock Titan

Thu, 11 Dec 2025
MAIA Biotechnology (MAIA) doses first patient in THIO-104 Phase 3 NSCLC trial - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.